Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chairperson, President and Chief Executive Officer.
2024年6月17日康涅狄格州紐黑文（GLOBE NEWSWIRE）報道——使用基於靶向蛋白降解的新型藥物開發的臨床階段生物技術公司Arvinas Inc.（Nasdaq: ARVN）宣佈，Ian Taylor博士已晉升爲研發總裁，Angela Cacace博士也晉升並將接替Taylor博士擔任首席科學家。Taylor博士和Cacace博士將立即擔任這些新職務，並向主席兼總裁兼首席執行官John Houston博士報告。
"These promotions reflect the contributions of both Ian and Angela to our success at Arvinas, as well as their crucial roles in leading Arvinas through a new chapter in its evolution," said John Houston, Ph.D., Chairperson, President and Chief Executive Officer. "Ian has been a driving force at Arvinas for the past eight years, with his wealth of knowledge and passion for innovation, and we are thrilled to announce his promotion to President of R&D. In his new role, Ian will ensure our innovation efforts continue to push the boundaries of what is possible, keeping Arvinas at the forefront of our industry."
“這些晉升反映了Ian和Angela在Arvinas的成功中所做出的貢獻，以及他們在引領Arvinas迎接公司演變新篇章中所擔任的關鍵角色，“John Houston博士說。“過去八年來，Ian一直是Arvinas的推動力，憑藉他豐富的知識和不斷創新的熱情。我們非常高興地宣佈他晉升爲研發總裁。在他的新職務中，Ian將確保我們的創新努力繼續推動可能的邊界，讓Arvinas一直處於我們行業的前沿。”
Dr. Taylor joined Arvinas in 2016 as Vice President of Pharmacology and Translational Medicine and has held positions of increasing responsibility, including serving as Chief Scientific Officer of the company since early 2019. Prior to Arvinas, Dr. Taylor had long tenures at Bayer and Pfizer, where he held leadership roles in Oncology Research and Development, respectively. As President of R&D, Dr. Taylor will provide strategic input across the company's broad pipeline, from early research efforts to multiple development programs in oncology and neuroscience. Dr. Taylor will continue to be an important connection to outside stakeholders, including thought leaders, strategic partners, and investors, and will also chair the Company's Scientific Advisory Board, with whom he's worked since joining Arvinas.
Taylor博士於2016年加入Arvinas，擔任藥理學和轉化醫學副總裁，並擔任公司首席科學家等越來越重要的職務。在加入Arvinas之前，Taylor博士在拜耳和輝瑞工作了很長時間，分別擔任腫瘤學研究和開發的領導職務。作爲研發總裁，Taylor博士將提供戰略性的指導，覆蓋公司廣泛的產品線，從早期的研究工作到腫瘤學和神經科學的多個開發計劃。Taylor博士將繼續是公司與外部利益相關者的重要聯繫人，包括思想領袖、戰略合作伙伴和投資者，並主持公司的科學顧問委員會，與他自加入Arvinas以來一直共事。
"I am honored to take on this new role at Arvinas," said Dr. Taylor. "I am very proud of what we have already accomplished as a company and have an unwavering conviction that the future of Arvinas is even brighter, given the incredible strength of our clinical portfolio and the research pipeline that we've built. I look forward to continuing to play a strategic role, along with John and the leadership team, to bring our PROTAC protein degraders to patients. Angela is ideally suited to be our next Chief Scientific Officer and she will step in to that position seamlessly."
泰勒博士說:"能夠擔任Arvinas公司的新角色，我感到非常榮幸。我們作爲一個公司已經取得了非常大的成就，我堅信，在我們擁有的臨床組合實力和研發計劃的基礎上，Arvinas的未來會更加美好。我期待繼續與約翰和領導團隊一起發揮戰略作用，帶領我們的PROTAC“在我們成功中，Angela發揮了關鍵作用，我很高興能晉升她爲首席科學家，”Houston博士繼續說道。“她在過去六年中的遠見卓識幫助我們構建了我們的神經科學和平台能力，並推動我們提名ARV-102，Arvinas第一個用於神經退行性疾病的PROTAC降解劑進入臨床開發。憑藉她在癌症生物學和癌症藥物研究方面的深厚科學技術知識，我相信作爲首席科學家，Angela將繼續推動我們的研發產品隊列向前發展。”
"Angela has been instrumental in our success and I am excited we are promoting her to Chief Scientific Officer," continued Dr. Houston. "Her visionary approach over the past six years at Arvinas helped to build our neuroscience and platform capabilities and she was a driving force in our nomination of ARV-102, Arvinas' first investigational PROTAC degrader for neurodegeneration, into clinical development. With her deep scientific and technical expertise in cancer biology and cancer drug discovery, I am confident that as CSO, Angela will continue to drive our research pipeline forward."
Cacace博士於2018年加入Arvinas，擔任神經科學和平台生物學副總裁，擁有兩個專業領域20多年的藥物發現經驗，分別是神經科學和腫瘤學研究。她最近擔任高級副總裁，神經科學和平台生物學。她在輝瑞的前一份工作是專注於腫瘤抗體藥物研發項目，推出一種抗血管生成的臨床候選藥物。在Bristol-Myers Squibb，這個因研發而聞名的研究領域的幾種職位以及在Fulcrum Therapeutics任職生物學負責人期間，她構建了創新的管道、發展了有才華的科學團隊、提供了多個臨床候選人，並指導制定轉化生物標記物以支持臨床開發計劃。在過去的六年中，與Arvinas團隊一起，Cacace博士一直領導着Arvinas強大的PROTAC發現引擎，採用新的E3連接酶和十字血腦屏障，針對多種神經邏輯疾病靶位，包括將PROTAC LRRK2降解劑ARV-102輸送到正在進行的臨床試驗中。
Dr. Cacace joined Arvinas in 2018 as Vice President of Neuroscience and Platform Biology, bringing over two decades of drug discovery experience in neuroscience and oncology research across modalities. She most recently served as Senior Vice President, Neuroscience and Platform Biology. Her prior experience at Pfizer focused on oncology antibody drug discovery efforts to deliver an anti-angiogenic clinical candidate. While at Bristol-Myers Squibb, in positions of increasing responsibility in research, and as head of biology at Fulcrum Therapeutics, she built innovative pipelines, grew talented scientific teams, delivered multiple clinical candidates, and guided the development of translational biomarkers to enable clinical development programs. Over the past six years, together with the Arvinas team, Dr. Cacace has led the continuous evolution of Arvinas' powerful PROTAC Discovery Engine to employ new E3 ligases and cross the blood-brain barrier for multiple neurologic disease targets, including the delivery of PROTAC LRRK2 degrader ARV-102 into ongoing clinical trials.
Cacace博士於2018年加入Arvinas擔任神經科學和平台生物學副總裁，擁有超過20年的神經科學和腫瘤學藥物發現經驗。她最近擔任高級副總裁，神經科學和平台生物學。她在Pfizer的前任工作主要關注於腫瘤抗體藥物的發現，以提供一種抗血管生成臨床候選藥物。在Bristol-Myers Squibb任職期間，她在研究部門職位逐漸提高，並在Fulcrum Therapeutics擔任生物學主管，建立了創新的管線，培養了才華橫溢的科研團隊，提供了多個臨床候選藥物，並指導了轉化生物標誌物的發展，從而爲臨床開發計劃打下了基礎。在過去的六年中，Cacace博士與Arvinas團隊一起，持續推進了Arvinas的強大的PROTAC的發展Cacace博士於2018年加入Arvinas，擔任神經科學和平台生物學副總裁，擁有兩個專業領域20多年的藥物發現經驗，分別是神經科學和腫瘤學研究。她最近擔任高級副總裁，神經科學和平台生物學。她在輝瑞的前一份工作是專注於腫瘤抗體藥物研發項目，推出一種抗血管生成的臨床候選藥物。在Bristol-Myers Squibb，這個因研發而聞名的研究領域的幾種職位以及在Fulcrum Therapeutics任職生物學負責人期間，她構建了創新的管道、發展了有才華的科學團隊、提供了多個臨床候選人，並指導制定轉化生物標記物以支持臨床開發計劃。在過去的六年中，與Arvinas團隊一起，Cacace博士一直領導着Arvinas強大的PROTAC發現引擎，採用新的E3連接酶和十字血腦屏障，針對多種神經邏輯疾病靶位，包括將PROTAC LRRK2降解劑ARV-102輸送到正在進行的臨床試驗中。Cacace博士於2018年加入Arvinas，擔任神經科學和平台生物學副總裁，擁有兩個專業領域20多年的藥物發現經驗，分別是神經科學和腫瘤學研究。她最近擔任高級副總裁，神經科學和平台生物學。她在輝瑞的前一份工作是專注於腫瘤抗體藥物研發項目，推出一種抗血管生成的臨床候選藥物。在Bristol-Myers Squibb，這個因研發而聞名的研究領域的幾種職位以及在Fulcrum Therapeutics任職生物學負責人期間，她構建了創新的管道、發展了有才華的科學團隊、提供了多個臨床候選人，並指導制定轉化生物標記物以支持臨床開發計劃。在過去的六年中，與Arvinas團隊一起，Cacace博士一直領導着Arvinas強大的PROTAC發現引擎，採用新的E3連接酶和十字血腦屏障，針對多種神經邏輯疾病靶位，包括將PROTAC LRRK2降解劑ARV-102輸送到正在進行的臨床試驗中。
"I am thrilled to take on this role at Arvinas during this crucial stage in our company's journey," said Dr. Cacace. "I have long been committed to fostering a collaborative and innovative environment that advances our pipeline from early discovery through clinical development. By integrating our scientific efforts with our overall business strategy, we aim to accelerate the translation of our targeted protein degradation research into meaningful clinical trials and potentially impactful treatments. Patients are at the heart of everything we do, and we will continue to push the boundaries of science with urgency and purpose."
“我很高興能在這個關鍵時期加入Arvinas，”Cacace博士說。“我一直致力於營造一種協作創新的環境，以推動我們優化從早期的發現到臨床研發的藥物管道。通過將我們的科學事業與我們的整體業務戰略相融合，我們旨在加速將有針對性的蛋白質降解研究轉化爲有意義的臨床試驗和可能具有影響力的治療方案。患者是我們所做的一切，我們將繼續以緊迫性和目的驅動的方式推動科學的邊界。”
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit us on www.arvinas.com, which does not form part of this release, and connect with us on LinkedIn and X.
關於Arvinas
Arvinas（納斯達克股票代碼：ARVN）是一家臨床階段的生物技術公司，致力於改善患有致命疾病和影響生活質量的患者的生活。通過其蛋白質降解平台PROTAC（PROteolysis Targeting Chimera），該公司正在開創蛋白質降解療法的發展，旨在利用人體本身的蛋白質清除系統有選擇地、高效地降解和消除引起疾病的蛋白質。Arvinas目前正在通過臨床開發計劃推進多種研究藥物，包括針對雌激素受體的奧司他樂（vepdegestrant）治療局部晚期或轉移性ER+/HER2-乳腺癌的瑞緹（rti）；針對LRRK2的ARV-102治療神經退行性疾病；以及針對復發/難治非霍奇金淋巴瘤的BCL6的ARV-393。Arvinas總部位於康涅狄格州紐黑文。欲了解Arvinas的更多信息，請訪問我們的網站，或通過LinkedIn與聯繫我們。https://arvinas.com/www.arvinas.com此新聞稿不包含於此說明中，有關新聞稿及有關照片請點擊鏈接:LinkedIn和頁面。X.
Arvinas Forward-Looking Statements
Arvinas前瞻性聲明
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding Arvinas' ability to bring its technology to patients, including its ability to accelerate the translation of its targeted protein degradation research into meaningful clinical trials and impactful treatment; the potential therapeutic benefits of the product candidates in Arvinas' PROTAC protein degrader pipeline; the future of Arvinas based on strength of its clinical portfolio and research pipeline; and the impact the enumerated promotions may have on the company. The words "believe," "expect," "may," "plan," "potential," "will," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made as a result of various risks and uncertainties, including but not limited to: Arvinas' approach to the discovery and development of product candidates based on its PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products; Arvinas' ability to protect its intellectual property position; whether cash and cash equivalent resources will be sufficient to fund Arvinas' foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date after the date of this release.
本新聞發佈稿件包含根據1995年《私人證券訴訟改革法》（Private Securities Litigation Reform Act of 1995）的有利根據的前瞻性聲明，涉及到Arvinas將其技術帶給患者的能力，包括其加速將有針對性的蛋白質降解研究轉化爲有意義的臨床試驗和具有影響力的治療，Arvinas的PROTAC蛋白質降解劑管道中的產品候選人的潛在治療效益，以及上述晉升可能對公司產生的影響。雖然並非所有前瞻性聲明均包含這些識別性字，如“認爲”、“期望”、“可能”、“計劃”、“潛在”、“將”、“持續”等等，但閱讀者可以通過這些識別性字判斷爲前瞻性聲明。Arvinas無法確保實際上能夠達到這些前瞻性聲明中所透露的計劃、意圖或預期，因此您不應對這些前瞻性聲明的實際結果或事件表示過多關注。由於各種風險和不確定因素的影響，Arvinas實際上可能無法如計劃、意圖或預期的那樣實現和披露這些前瞻性聲明。具體風險和不確定性包括但不限於：Arvinas的基於PROTAC技術平台的產品候選人的開發方式尚未證明，這使得難以預測開發的時間、開發成本和成功開發任何產品的可能性；Arvinas的保護知識產權的能力；現金和現金等價物資源是否足以支撐Arvinas可預測和不可預測的營業費用和資本支出需求；以及有關該公司全年的“風險因素”部分的重要因素。對於未來事件，本新聞發佈稿件中的前瞻性聲明僅代表當前觀點，Arvinas假設除適用法律規定外，不會更新任何前瞻性聲明。您不應該將這些前瞻性聲明視爲自本發佈日期起代表Arvinas觀點的陳述。
Contacts
聯繫方式
Investor Contact:
Jeff Boyle, Arvinas Investor Relations
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
投資者聯繫人：
Jeff Boyle, Arvinas投資者關係
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media Contact:
Kathleen Murphy, Arvinas Communications
+1 (760) 622-3771
Kathleen.Murphy@arvinas.com
媒體聯繫人：
Kathleen Murphy, Arvinas通信
+1 (760) 622-3771
Kathleen.Murphy@arvinas.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/4b3b7113-9acc-4f80-aea9-1930844e31d8